News

BASF & CSM form joint venture
Enlarge image

BusinessGermanyNetherlands

BASF & CSM form joint venture

08.10.2012 - German chemicals giant and Dutch CSM daughter Purac have formed a
50/50 joint venture to produce and market biobased succinic acid.

The largest chemical firm of the world, BASF SE (Ludwigshafen, Gemany), and the leading producer of biobased lactic acid, Purac NV (Diemen, The Netherlands), a subsidiary of Dutch CSM, have formed a joint venture. After three years of testing of a novel fermentation process on pre-industrial scale at Purac’s production site in Montmélo near Barcelona, Succinity GmbH is going to start the production and sale of biobased succinic acid from 2013 . Succinity, which will be headquartered in Düsseldorf Germany, will be the third player in the market for biologically produced succinic acid, an important chemical building block for making 1,4-butanediol (1,4-BDO), tetrahydrofuran (THF) and gamma-butyrolactone (GBL). These bulk chemicals are needed for making polyesters, polyurethanes, spandex and biodegradable plastics with a global market value of more than $4bn.

BASF and CSM are currently expand Purac’s fermentation facility to deliver an annual capacity of 10,000 metric tons of succinic acid from late 2013. This is complemented by plans for a second large-scale facility with an annual capacity of 50,000 metric tons of succinic acid to enable the company to respond to the expected increase in demand. The final investment decision for this facility will be made following a successful market introduction, according to the companies.

Despite stiff competition from Reverdia, a joint-venture of Dutch DSM and French Roquette, and US-headquartered BioAmber Inc., BASF wants to take a leading position in the market. „The market is large enough for all players“, said BASF spokesman Holger Kapp to EuroBiotechNews. Earlier this year, Reverdia announced it will start biosuccinate production at the end of 2012. At the beginning of 2011, BioAmber had already started production of 2,000 metric tons of biosuccinate at its French production site in Pomacle and has since then expanded its production and its capacities to produce 1,4-BDO. However, BASF has brought in a unique production technology. Its proprietary microorganism Basfia succiniciproducens can make  biobased succinic acid either from plant-made sugars or by glycerol, a waste product form biodiesel production. This might give Succinity a competitive edge over the competitor’s technologies that can only convert crop- or plant-made sugars.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/basf-csm-form-joint-venture.html

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

M&AIreland

08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)9.85 SEK15.20%
  • ZEALAND PHARMA (DK)158.00 DKK12.86%
  • ERYTECH PHARMA (F)36.51 EUR6.13%

FLOP

  • FLAMEL TECHNOLOGIES (F)23.00 USD-10.47%
  • ZELTIA (E)3.69 EUR-8.44%
  • WILEX (D)3.28 EUR-6.29%

TOP

  • IXICO (UK)35.00 GBP55.6%
  • DBV TECHNOLOGIES (F)79.73 EUR53.7%
  • ZEALAND PHARMA (DK)158.00 DKK43.0%

FLOP

  • BIOTEST (D)25.73 EUR-63.2%
  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • BIOTECH PHARMACON (N)9.47 NOK-44.9%

TOP

  • ADOCIA (F)90.49 EUR580.9%
  • FORMYCON (D)28.68 EUR323.6%
  • DBV TECHNOLOGIES (F)79.73 EUR309.1%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-70.3%
  • NEOVACS (F)1.02 EUR-69.1%

No liability assumed, Date: 30.07.2015